These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

226 related items for PubMed ID: 32065066

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Contrast-enhanced ultrasound evaluation of pancreatic cancer xenografts in nude mice after irradiation with sub-threshold focused ultrasound for tumor ablation.
    Gao YH, Wu L, Wang R, Guo Q, Chen YN, Hu B, Jiang LX.
    Oncotarget; 2017 Jun 06; 8(23):37584-37593. PubMed ID: 28402267
    [Abstract] [Full Text] [Related]

  • 23. Dual targeting of vascular endothelial growth factor and bone morphogenetic protein-9/10 impairs tumor growth through inhibition of angiogenesis.
    Akatsu Y, Yoshimatsu Y, Tomizawa T, Takahashi K, Katsura A, Miyazono K, Watabe T.
    Cancer Sci; 2017 Jan 06; 108(1):151-155. PubMed ID: 28133920
    [Abstract] [Full Text] [Related]

  • 24. AG-013736, a novel inhibitor of VEGF receptor tyrosine kinases, inhibits breast cancer growth and decreases vascular permeability as detected by dynamic contrast-enhanced magnetic resonance imaging.
    Wilmes LJ, Pallavicini MG, Fleming LM, Gibbs J, Wang D, Li KL, Partridge SC, Henry RG, Shalinsky DR, Hu-Lowe D, Park JW, McShane TM, Lu Y, Brasch RC, Hylton NM.
    Magn Reson Imaging; 2007 Apr 06; 25(3):319-27. PubMed ID: 17371720
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Inhibition of vascular endothelial growth factor (VEGF) as a novel approach for cancer therapy.
    Wood JM.
    Medicina (B Aires); 2000 Apr 06; 60 Suppl 2():41-7. PubMed ID: 11188930
    [Abstract] [Full Text] [Related]

  • 27. The chemopreventive agent oltipraz possesses potent antiangiogenic activity in vitro, ex vivo, and in vivo and inhibits tumor xenograft growth.
    Ruggeri BA, Robinson C, Angeles T, Wilkinson J, Clapper ML.
    Clin Cancer Res; 2002 Jan 06; 8(1):267-74. PubMed ID: 11801568
    [Abstract] [Full Text] [Related]

  • 28. Intra-Animal Comparison between Three-dimensional Molecularly Targeted US and Three-dimensional Dynamic Contrast-enhanced US for Early Antiangiogenic Treatment Assessment in Colon Cancer.
    Wang H, Lutz AM, Hristov D, Tian L, Willmann JK.
    Radiology; 2017 Feb 06; 282(2):443-452. PubMed ID: 27490690
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor.
    Ciardiello F, Caputo R, Bianco R, Damiano V, Fontanini G, Cuccato S, De Placido S, Bianco AR, Tortora G.
    Clin Cancer Res; 2001 May 06; 7(5):1459-65. PubMed ID: 11350918
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Evaluation of high frequency ultrasound methods and contrast agents for characterising tumor response to anti-angiogenic treatment.
    Rix A, Lederle W, Siepmann M, Fokong S, Behrendt FF, Bzyl J, Grouls C, Kiessling F, Palmowski M.
    Eur J Radiol; 2012 Oct 06; 81(10):2710-6. PubMed ID: 22093958
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 12.